

# Helen Dakin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8739263/publications.pdf>

Version: 2024-02-01

38  
papers

1,247  
citations

430874

18  
h-index

377865

34  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1978  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Influence of Cost-Effectiveness and Other Factors on Nice Decisions. Health Economics (United Kingdom), 2011, 31, 107-124.	1.7	166
2	Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open, 2012, 2, e000332.	1.9	144
3	Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health and Quality of Life Outcomes, 2013, 11, 151.	2.4	126
4	Patellar Resurfacing in Total Knee Replacement: Five-Year Clinical and Economic Results of a Large Randomized Controlled Trial. Journal of Bone and Joint Surgery - Series A, 2011, 93, 1473-1481.	3.0	77
5	Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement. Health and Quality of Life Outcomes, 2018, 16, 31.	2.4	77
6	The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. Pharmacoeconomics, 2015, 33, 993-1011.	3.3	70
7	COST-MINIMISATION ANALYSIS VERSUS COST-EFFECTIVENESS ANALYSIS, REVISITED. Health Economics (United Kingdom), 2013, 22, 22-34.	1.7	64
8	Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2-factorial, randomised controlled trial. Lancet, The, 2021, 398, 416-428.	13.7	53
9	Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Quality of Life Research, 2013, 22, 683-694.	3.1	51
10	Mapping analyses to estimate health utilities based on responses to the OM8-30 otitis media questionnaire. Quality of Life Research, 2010, 19, 65-80.	3.1	43
11	Cost-Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health, 2010, 13, 922-933.	0.3	35
12	Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B. Value in Health, 2010, 13, 934-945.	0.3	34
13	The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty. Bone and Joint Journal, 2020, 102-B, 941-949.	4.4	30
14	The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling. Health Technology Assessment, 2019, 23, 1-216.	2.8	28
15	Cost-Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. Clinical Therapeutics, 2007, 29, 1491-1507.	2.5	24
16	Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations. Statistics in Medicine, 2017, 36, 2814-2830.	1.6	23
17	Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia. Clinical Drug Investigation, 2008, 28, 583-601.	2.2	21
18	Cost-Utility Analysis of Topical Intra-nasal Steroids for Otitis Media with Effusion Based on Evidence from the GNOME Trial. Value in Health, 2010, 13, 543-551.	0.3	21

#	ARTICLE	IF	CITATIONS
19	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Pharmacoeconomics</i> , 2015, 33, 985-991.	3.3	21
20	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	2.4	15
21	Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. <i>Quality of Life Research</i> , 2016, 25, 275-281.	3.1	14
22	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 106.	2.4	13
23	Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions. <i>Medical Decision Making</i> , 2018, 38, 476-486.	2.4	13
24	Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 302.	1.9	13
25	Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-158.	2.8	10
26	The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHOES): a virtual randomised balanced incomplete block trial. <i>Health Technology Assessment</i> , 2016, 20, 1-120.	2.8	9
27	Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective. <i>Pharmacoeconomics</i> , 2011, 29, 1075-1091.	3.3	8
28	Response Mapping to Translate Health Outcomes into the Generic Health-Related Quality-of-Life Instrument EQ-5D: Introducing the mrs2eq and oks2eq Commands. <i>The Stata Journal</i> , 2013, 13, 474-491.	2.2	8
29	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 230-235.	0.5	7
30	Partial factorial trials: comparing methods for statistical analysis and economic evaluation. <i>Trials</i> , 2018, 19, 442.	1.6	7
31	Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L. <i>Quality of Life Research</i> , 2016, 25, 935-945.	3.1	6
32	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Journal of Medical Economics</i> , 2015, 18, 851-857.	2.1	4
33	Who gets referred for knee or hip replacement? A theoretical model of the potential impact of evidence-based referral thresholds using data from a retrospective review of clinic records from an English musculoskeletal referral hub. <i>BMJ Open</i> , 2020, 10, e028915.	1.9	4
34	Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2ÅÅ– 2ÅÅ– 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. <i>Value in Health</i> , 2020, 23, 1340-1348.	0.3	3
35	Moulded cast compared with K-wire fixation after manipulation of an acute dorsally displaced distal radius fracture: the DRAFFT 2 RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-80.	2.8	2
36	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Medical Decision Making</i> , 2015, 35, NP1-NP8.	2.4	1

#	ARTICLE	IF	CITATIONS
37	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 437-443.	2.1	1
38	Which interactions matter in economic evaluations? A systematic review and simulation study. <i>BMC Medical Research Methodology</i> , 2020, 20, 109.	3.1	1